<html lang="en"><head>
    <!--<title>Leading Global Pharmaceutical Company in India - Zydus group - Zydus</title>-->
    <title>Zydus pharma Research Center | Vaccine Technology Centre In India</title>
    <meta name="description" content="Zydus Group research-based pharmaceutical company in India is constantly exploring opportunities in pharma research, exploring different ideas, concepts &amp; continuously innovating.">
    <meta name="keywords" content="pharma research center india, research based pharmaceutical companies, vaccine technology centre india, bioresearch center India, Zydus research center">
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

	
    <meta name="csrf-token" content="urzFUnR2AMItMqJXzJaC9ZYTRXbC3yCu4E4m5AHW">

 
    <meta name="viewport" content="width=device-width, initial-scale=1">
	<link rel="canonical" href="https://zyduscadila.com">
 
    <link rel="shortcut icon" type="image/x-icon" href="https://www.zyduslife.com/public/images/favicon.ico">
    <link rel="stylesheet" type="text/css" href="https://www.zyduslife.com/public/css/bootstrap.min.css">
    <link rel="stylesheet" type="text/css" href="https://www.zyduslife.com/public/css/fonts.css">
    <link rel="stylesheet" type="text/css" href="https://www.zyduslife.com/public/css/fa.css">
    <link rel="stylesheet" type="text/css" href="https://www.zyduslife.com/public/css/owl.carousel.min.css">
    <link rel="stylesheet" type="text/css" href="https://www.zyduslife.com/public/css/styles.css">
    <link rel="stylesheet" type="text/css" href="https://www.zyduslife.com/public/css/developer.css">
    <link rel="stylesheet" type="text/css" href="https://www.zyduslife.com/public/css/accordion.css">
    <link href="https://fonts.googleapis.com/css2?family=Exo:wght@100;200;300;400;500;600;700;800;900&amp;display=swap" rel="stylesheet">
    
    <!--[if lte IE 9]>
    <div id="ie-toolbar">
        <div>You're using an unsupported version of Internet Explorer. Please
            <a href="http://windows.microsoft.com/en-us/internet-explorer/products/ie/home" target="_blank"
               rel="noopener noreferrer">upgrade your browser</a> for the best user experience on our site. Thank you.
        </div>
    </div>
    <![endif]-->
    <script type="text/javascript" async="" src="https://www.google-analytics.com/analytics.js"></script><script>
        document.onkeydown = function(e) {
            if(event.keyCode == 123) {
                return false;
            }
            if(e.ctrlKey && e.shiftKey && e.keyCode == 'I'.charCodeAt(0)){
                return false;
            }
            if(e.ctrlKey && e.shiftKey && e.keyCode == 'J'.charCodeAt(0)){
                return false;
            }
            if(e.ctrlKey && e.keyCode == 'U'.charCodeAt(0)){
                return false;
            }
        }
    </script>
    <!-- Global site tag (gtag.js) - Google Analytics -->
<script async="" src="https://www.googletagmanager.com/gtag/js?id=UA-195953504-35"></script>
<script>
 window.dataLayer = window.dataLayer || [];
 function gtag(){dataLayer.push(arguments);}
 gtag('js', new Date());

 gtag('config', 'UA-195953504-35');
</script>
</head>
<body class="" style="">
        <div style="display:none" id="sbbhscc"></div>
          <script type="text/javascript">
            var sbbvscc='';
            var sbbgscc='';
            function genPid() {return String.fromCharCode(82)+String.fromCharCode(82) ; };
          </script>
        <div id="sbbfrcc" style="position: absolute; top: -10px; left: 30px; font-size:1px"><img src="https://www.zyduslife.com/sbbi/?sbbpg=utMedia&amp;vii=5h643f3cae640a4832d3548781050ee0f1d81d897c1656eb5cd9915f4211353dv3r3i7g9"><iframe id="SBBCrossIframe" title="SBBCrossIframe" lang="en" aria-hidden="true" scrolling="NO" src="https://www.zyduslife.com/sbbi/?sbbpg=sbbShell&amp;gprid=RR&amp;sbbgs=h4fce4a8234715e018d9c66bc91f215d3379&amp;ddl=4" style="visibility: hidden; border: 0px; height: 1px; width: 0px;"></iframe></div>
  <script type="text/javascript">(function(XHR){var open=XHR.prototype.open;var send=XHR.prototype.send;var parser=document.createElement('a');XHR.prototype.open=function(method, url, async, user, pass){if(typeof async=='undefined'){async=true;}parser.href=url;if(parser.host==''){parser.href=parser.href;}this.ajax_hostname=parser.hostname;open.call(this, method, url, async, user, pass);};XHR.prototype.send=function(data){if(location.hostname==this.ajax_hostname)this.setRequestHeader("X-MOD-SBB-CTYPE", "xhr");send.call(this, data);}})(XMLHttpRequest);if(typeof(fetch)!="undefined"){var nsbbfetch=fetch;fetch=function(url, init){if(typeof(url)==="object" && typeof(url.url)==="string"){init={method: url.method, mode: url.mode, cache: url.cache, credentials: url.credentials, headers: url.headers, body: url.body};url=url.url;}function sbbSd(url, domain){var parser=document.createElement('a');parser.href=url;if(parser.host==''){parser.href=parser.href;}return parser.hostname==location.hostname;}if(sbbSd(url, document.domain)){init=typeof init !=='undefined' ? init :{};if(typeof(init.headers)==="undefined"){init.headers={};}init.headers['X-MOD-SBB-CTYPE']='fetch';}return nsbbfetch(url, init);};}function sbbgc(check_name){var start=document.cookie.indexOf(check_name+"=");var oVal='';var len=start+check_name.length+1;if((!start)&&(document.cookie.substring(0,check_name.length)!=check_name)){oVal='';}else if(start==-1){oVal='';}else{var end=document.cookie.indexOf(';',len);if(end==-1)end=document.cookie.length;var oVal=document.cookie.substring(len,end);};return oVal;}function addmg(inm,ext){var primgobj=document.createElement('IMG');primgobj.src=window.location.protocol+"//"+window.location.hostname+(window.location.port && window.location.port!=80 ? ':'+window.location.port: '')+"/sbbi/?sbbpg="+inm+(ext?"&"+ext:"");var sbbDiv=document.getElementById('sbbfrcc');sbbDiv.appendChild(primgobj);};function addprid(prid){var oldVal=sbbgc("PRLST");if((oldVal.indexOf(prid)==-1)&&(oldVal.split('/').length<5)){if(oldVal!=''){oldVal+='/';}document.cookie='PRLST='+oldVal+escape(prid)+';path=/; SameSite=Lax;';}}var sbbeccf=function(){this.sp3="jass";this.sf1=function(vd){return sf2(vd)+32;};var sf2=function(avd){return avd*12;};this.sf4=function(yavd){return yavd+2;};var strrp=function(str, key, value){if(str.indexOf('&'+key+'=')> -1 || str.indexOf(key+'=')==0){var idx=str.indexOf('&'+key+'=');if(idx==-1)idx=str.indexOf(key+'=');var end=str.indexOf('&', idx+1);var newstr;if(end !=-1)newstr=str.substr(0, idx)+str.substr(end+(idx ? 0 : 1))+'&'+key+'='+value;else newstr=str.substr(0, idx)+'&'+key+'='+value;return newstr;}else return str+'&'+key+'='+value;};var strgt=function(name, text){if(typeof text !='string')return "";var nameEQ=name+"=";var ca=text.split(/[;&]/);for(var i=0;i < ca.length;i++){var c=ca[i];while(c.charAt(0)==' ')c=c.substring(1, c.length);if(c.indexOf(nameEQ)==0)return c.substring(nameEQ.length, c.length);}return "";};this.sfecgs={sbbgh:function(){var domain=document.location.host;if(domain.indexOf('www.')==0)domain=domain.replace('www.', '');return domain;}, f:function(name, value){var fv="";if(window.globalStorage){var host=this.sbbgh();try{if(typeof(value)!="undefined")globalStorage[host][name]=value;else{fv=globalStorage[host][name];if(typeof(fv.toString)!="undefined")fv=fv.toString();}}catch(e){}}return fv;}, name:"sbbrf"};this.sfecls={f:function(name, value){var fv="";try{if(window.localStorage){if(typeof(value)!="undefined")localStorage.setItem(name, value);else{fv=localStorage.getItem(name);if(typeof(fv.toString)!="undefined")fv=fv.toString();}}}catch(e){}return fv;}, name:"sbbrf"};this.sbbcv=function(invl){try{var invalArr=invl.split("-");if(invalArr.length>1){if(invalArr[0]=="A"||invalArr[0]=="D"){invl=invalArr[1];}else invl="";}if(invl==null||typeof(invl)=="undefined"||invl=="falseImgUT"||invl=="undefined"||invl=="null"||invl!=encodeURI(invl))invl="";if(typeof(invl).toLowerCase()=="string")if(invl.length>20)if(invl.substr(0,2)!="h4")invl="";}catch(ex){invl="";}return invl;};this.sbbsv=function(fv){for(var elm in this){if(this[elm].name=="sbbrf"){this[elm].f("altutgv2",fv);}}document.cookie="UTGv2="+fv+';expires=Sat, 18-Feb-23 22:07:39 GMT;path=/; SameSite=Lax;';};this.sbbgv=function(){var valArr=Array();var currVal="";for(var elm in this){if(this[elm].name=="sbbrf"){currVal=this[elm].f("altutgv2");currVal=this.sbbcv(currVal);if(currVal!="")valArr[currVal]=(typeof(valArr[currVal])!="undefined"?valArr[currVal]+1:1);}}var lb=0;var fv="";for(var val in valArr){if(valArr[val]>lb){fv=val;lb=valArr[val]}}if(fv=="")fv=sbbgc("UTGv2");fv=this.sbbcv(fv);if(fv!="")this.sbbsv(fv);else this.sbbsv("D-h4fce4a8234715e018d9c66bc91f215d3379");return fv;};};function m2vr(m1,m2){var i=0;var rc="";var est="ghijklmnopqrstuvwyz";var rnum;var rpl;var charm1=m1.charAt(i);var charm2=m2.charAt(i);while(charm1!=""||charm2!=""){rnum=Math.floor(Math.random()* est.length);rpl=est.substring(rnum,rnum+1);rc+=(charm1==""?rpl:charm1)+(charm2==""?rpl:charm2);i++;charm1=m1.charAt(i);charm2=m2.charAt(i);}return rc;}function sbbls(prid){try{var eut=sbbgc("UTGv2");window.sbbeccfi=new sbbeccf();window.sbbgs=sbbeccfi.sbbgv();if(eut!=sbbgs && sbbgs!="" && typeof(sbbfcr)=="undefined"){addmg('utMedia',"vii="+m2vr("5633a6043d58800efd18715e5d954133",sbbgs));}var sbbiframeObj=document.createElement('IFRAME');var dfx=new Date();sbbiframeObj.id='SBBCrossIframe';sbbiframeObj.title='SBBCrossIframe';sbbiframeObj.tabindex='-1';sbbiframeObj.lang='en';sbbiframeObj.style.visibility='hidden';sbbiframeObj.setAttribute('aria-hidden', 'true');sbbiframeObj.style.border='0px';if(document.all){sbbiframeObj.style.position='absolute';sbbiframeObj.style.top='-1px';sbbiframeObj.style.height='1px';sbbiframeObj.style.width='28px';}else{sbbiframeObj.style.height='1px';sbbiframeObj.style.width='0px';}sbbiframeObj.scrolling="NO";sbbiframeObj.src=window.location.protocol+"//"+window.location.hostname+(window.location.port && window.location.port!=80 ? ':'+window.location.port: '')+'/sbbi/?sbbpg=sbbShell&gprid='+prid + '&sbbgs='+sbbgs+'&ddl='+(Math.round(dfx.getTime()/1000)-1661206059)+'';var sbbDiv=document.getElementById('sbbfrcc');sbbDiv.appendChild(sbbiframeObj);}catch(ex){;}}try{var y=unescape(sbbvscc.replace(/^<\!\-\-\s*|\s*\-\->$/g,''));document.getElementById('sbbhscc').innerHTML=y;var x=unescape(sbbgscc.replace(/^<\!\-\-\s*|\s*\-\->$/g,''));}catch(e){x='function genPid(){return "jser";}';}try{if(window.gprid==undefined)document.write('<'+'script type="text/javascri'+'pt">'+x+"var gprid=genPid();addprid(gprid);sbbls(gprid);<"+"/script>");}catch(e){addprid("dwer");}</script><script type="text/javascript">var gprid=genPid();addprid(gprid);sbbls(gprid);</script>
    <header class="header">
    <div class="headerInner">
        <a href="javascript:void(0);" class="menuText"><img src="https://www.zyduslife.com/public/images/menu.png"></a>
        <a href="https://www.zyduslife.com" class="logo"><img src="https://www.zyduslife.com/public/images/zydus-logo.png" alt="Zydus Logo"></a>
        
        <div class="menuBox" style="display: none;">
            <div class="menu">
                <ul class="cf">
                    <li><a href="https://www.zyduslife.com/"><span class="icons01"></span>Home</a></li>
                    <li><a href="company"><span class="icons02"></span>The Company</a></li>
                    <li><a href="operations"><span class="icons03"></span>Operations</a></li>
                    <li><a href="research"><span class="icons04"></span>Research</a></li>
                    <li><a href="products"><span class="icons05"></span>Products</a></li>
                    <li><a href="news"><span class="icons06"></span>News Updates</a></li>
                    <li><a href="investorzone"><span class="icons07"></span>Investor Zone</a></li>
                    <li><a href="career"><span class="icons08"></span>Careers</a></li>
                    <li><a href="mediakit"><span class="icons09"></span>Media Kit</a></li>
                    <li><a href="contactus"><span class="icons10"></span>Contact us</a></li>
                </ul>
               <a class="subscribeLink" data-toggle="modal" id="myBtn"><span></span>Subscribe to our Newsletter</a>
                <a onclick="location.href='javascript:void(0);'" class="closeMenu">×</a>
            </div>
        </div>
        
    </div>
</header>

    <style type="text/css">
.innovation:hover {
    color: #fff;
}
.innovation{
    color: #fff;
}
.innovation:focus{
	color: #fff;
	}
    .num li:before{
        content: none;
    }
    .num li{
        list-style: decimal;
    }
.ulArrow li::before {
    content: unset !important;
    }
#lidecimal li {
    list-style-type: decimal !important;
}
span.pad25 {
    padding-left: 81px;
    position: initial;
}
span.wid {
/*    width: 70px;
    position: absolute;*/
}

td.tbodystatus table td {
    padding: 4px !important;
}
.custwidth .col-sm-6{
    width: 33%;
}

	</style>
<div class="banner minHeight">
    <div class="innerBanner">
        <div class="item cf">
            <div class="research-mob mobileBanner"><img src="https://www.zyduslife.com/public/images/research-banner.jpg" alt="Research Banner"></div>
            <div class="bannerText">
                <h1>RESEARCH</h1>
                <p>Driven by passion for innovation, making a difference in the world of health and care</p>
            </div>
        </div>
    </div>
    <div class="follows_us">
    <a href="https://twitter.com/ZydusUniverse" target="_blank" rel="noopener noreferrer">
        <img src="https://www.zyduslife.com/public/images/icons/twitter-icon.png" alt="twitter">
    </a>
    <a href="https://www.linkedin.com/company/zyduscadila" target="_blank" rel="noopener noreferrer">
        <img src="https://www.zyduslife.com/public/images/icons/linkdin-icon.png" alt="linkedin"> </a> <span class="line"> &nbsp;</span> <span class="follow"> Follow Us</span>
</div></div>
<div class="container">
    <h2 class="hideMob"><span id="researchpipeline" class="idName"></span></h2>
    <p><strong>Innovation Excellence is unleashed when ideas are spurred by action, making the impossible happen.</strong></p>
    <p>As a research-based pharmaceutical company, Zydus' Innovation programme is spearheaded by 1300 researchers across 19 sites, working on differentiated medicines for the future. From NCEs to vaccines, biosimilars and niche technologies, the group is exploring different ideas, concepts and continuously innovating. </p>

    <h3>Major Areas of Research:</h3>
        <div class="row threeBox">
        <div class="col-md-4">
            <div class="pull-left"> <img src="https://www.zyduslife.com/public/images/zydus_2022/icons/nce_research.png" alt="NCE Research"> <strong class="detail text-center">NCE RESEARCH</strong>
                <ul id="demo" class="list-unstyled text-center">
                    <li>Cardio-Metabolic diseases</li>
                    <li>Inflammation &amp; pain</li>
                    <li>Oncology</li>
                </ul>
            </div>
        </div>
        <div class="col-md-4">
            <div class="text-center"> <img src="https://www.zyduslife.com/public/images/zydus_2022/icons/biologics.png" alt="Biologics"> <strong class="detail text-center">BIOLOGICS</strong>
                <ul class="list-unstyled text-center">
                    <li>Biosimilar Therapeutic proteins</li>
                    <li>Biosimilar Monoclonal antibodies</li>
                    <li>Biobetters and Novel biologics</li>
                </ul>
            </div>
        </div>
        <div class="col-md-4">
            <div class="pull-right"> <img src="https://www.zyduslife.com/public/images/zydus_2022/icons/vaccines.png" alt="Vaccines"> <strong class="detail text-center">VACCINES</strong>
                <ul class="list-unstyled text-center">
                    <li>Infectious diseases</li>
                </ul>
            </div>
        </div>

        <div class="hideView-research" style="display: none;"><img src="https://www.zyduslife.com/public/images/our-research-spectrum.jpg" alt="Research Spectrum" class="imgW100p"></div>

        <div class="col-md-12 text-center clear">
            <button type="button" class="btn btnCss researchClick">View More</button>
        </div>

    </div>

    <h2>NEW CHEMICAL ENTITIES <span id="newchemicalentities" class="idName"></span></h2>
    <p>The Zydus Research Centre (ZRC) is the dedicated research arm of the Zydus Group. With its team of over 400 research professionals, ZRC spearheads the group’s quest of creating healthier and happier communities globally. Spread over an area of over 4,75,000 sq ft, ZRC is working on cutting edge technologies in different scientific disciplines to discover novel therapeutic agents. The centre has capabilities to conduct drug discovery &amp; development from concept to IND enabling preclinical and clinical studies.</p>
    <p>In 2013, the group was the first to identify, develop and launch Lipaglyn<sup>TM</sup>&nbsp;(Saroglitazar) the novel drug to treat diabetic dyslipidemia – a global, unmet healthcare need. Lipaglyn is the first NCE from an Indian research pipeline to move from the lab to the market. It offers dual benefits of lipid and glycemic control in one single molecule. It is an innovation that has helped over 700000 people suffering from diabetic dyslipidemia in India lead healthier lives. </p>
    <div class="panel-group accordion" id="accordion">
        <div class="panel panel-default">
            <div class="panel-heading">
                <h4 class="panel-title">
                    <!-- <a data-toggle="collapse" data-parent="#accordion" href="#collapse1">LipagIyn<sup>TM</sup> for treating Hypertriglyceridemia and Diabetic Dyslipidemia<i class="more-less glyphicon glyphicon-plus"></i></a> -->
                    <a data-toggle="collapse" data-parent="#accordion" href="#collapse1">Saroglitazar Mg&nbsp;<i class="more-less glyphicon glyphicon-plus"></i></a>
                </h4>
            </div>
            <div id="collapse1" class="panel-collapse collapse">
                <div class="panel-body">
                    <div class="col-md-12">
                        <p>Saroglitazar Mg currently approved in India is a prescription medicine for the treatment of Hypertriglyceridemia, Diabetic Dyslipidemia in Patients with Type 2 Diabetes not controlled by statins, Type 2 Diabetes and Non-Alcoholic SteatoHepatitis (NASH) &amp; Non Alcoholic Fatty Liver Disease (NAFLD) with comorbidities</p>
                        <!-- <p>Lipaglyn™ (Saroglitazar Mg) currently approved in India is a prescription medicine for the treatment of Hypertriglyceridemia and Diabetic Dyslipidemia in Patients with Type 2 Diabetes not controlled by statins. The recommended dose of Lipaglyn™ is 4 mg once-a-day.</p> -->
                        <p class="text-center"><img src="https://www.zyduslife.com/public/images/zydus-lipaglyn.jpg" class="img-responsive marginAuto" alt="Zydus Lipaglyn"></p>
                        <p>Saroglitazar Mg is an investigational new drug in the United States of America, and is currently being evaluated in Phase II clinical trials for the treatment of Non-Alcoholic SteatoHepatitis (NASH) and Primary Biliary Cholangitis (PBC). The USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for Primary Biliary Cholangitis (PBC).</p>

                        <!-- <p>Saroglitazar Mg is an investigational new drug in the United States and is currently being evaluated in Phase II clinical trials for the treatment of Severe Hypertriglyceridemia (TG &gt 500) and Non-Alcoholic SteatoHepatitis (NASH).</p> -->


                        <div class="imgList cf">
                            <img src="https://www.zyduslife.com/public/images/lipaglyn-1.jpg" class="img-responsive" alt="Hypertriglyceridemia">
                            <img src="https://www.zyduslife.com/public/images/lipaglyn-2.jpg" class="img-responsive" alt="Diabetic Dyslipidemia">
                            <img src="https://www.zyduslife.com/public/images/lipaglyn-5.jpg" class="img-responsive" alt="Type 2 Diabetes">
                            <img src="https://www.zyduslife.com/public/images/lipaglyn-6.jpg" class="img-responsive" alt="NAFLD">
                            <img src="https://www.zyduslife.com/public/images/lipaglyn-3.jpg" class="img-responsive" alt="NASH">
                            <img src="https://www.zyduslife.com/public/images/lipaglyn-4.jpg" class="img-responsive" alt="PBC">
                        </div>
                        <p></p>
                        <p>* Saroglitazar is a prescription drug authorised for sale in India only and can be taken only under the advice and guidance of a registered medical practitioner.</p>

                        <!-- <h3>NON-ALCOHOLIC STEATOHEPATITIS (NASH)</h3>
                        <p>Zydus has initiated a 52 week Phase III clinical trial of Lipaglyn™ in patients with biopsy proven NASH. Saroglitazar has demonstrated good efficacy in animal models of NASH, along with associated biomarkers. It has reduced hepatic steatosis, ballooning, inflammation and fibrosis in liver. Recently completed phase 2 studies of Saroglitazar in patients with biopsy proven NASH patients has shown improvement in liver enzymes along with favourable effects on lipid and glycemic indices.</p>
 -->
                        <h3>PUBLICATIONS:</h3>
                        <ul class="ulArrow cf" id="lidecimal">
                            
<li><a target="_blank" rel="noopener noreferrer" href="https://www.journal-of-hepatology.eu/article/S0168-8278(21)02023-7/fulltext">Vuppalanchi R, Caldwell SH, Pyrsopoulos N, deLemos AS, Rossi S, Levy C, Goldberg DS, Mena EA, Sheikh A, Ravinuthala R, Shaikh F, Bainbridge JD, Parmar DV, Chalasani NP. Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. J Hepatol. 2021 Sep 3:S0168-8278(21)02023-7. doi: 10.1016/j.jhep.2021.08.025. Epub ahead of print. PMID: 34487750</a></li>
                            <li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/33811367/">Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a PPAR-alpha/gamma Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021 Apr 2. doi: 10.1002/hep.31843. PMID: 3381136</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/33769355/">Vuppalanchi R, González-Huezo MS, Payan-Olivas R, Muñoz-Espinosa LE, Shaikh F, Pio Cruz-Lopez JL, Parmar D. A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis. Clin Transl Gastroenterol. 2021 Mar 26;12(4):e00327. doi: 10.14309/ctg.0000000000000327.PMID: 3376935</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/32518275/">Kumar DP, Caffrey R, Marioneaux J, Santhekadur PK, Bhat M, Alonso C, Koduru SV, Philip B, Jain MR, Giri SR, Bedossa P, Sanyal AJ.  The PPAR alpha/gamma Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. Sci Rep. 2020 Jun 9;10(1):9330. doi: 10.1038/s41598-020-66458-z.</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/33753107/">Joharapurkar A, Patel V, Kshirsagar S, Patel MS, Savsani H, Jain M. Effect of dual PPAR-alpha/gamma agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy. Eur J Pharmacol. 2021 May 15;899:174032. doi: 10.1016/j.ejphar.2021.174032. Epub 2021 Mar 19.PMID: 3375310</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/24062180/">Jani RH et al., Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARa Agonist with Moderate PPARc Agonist Activity in Healthy Human Subjects. Clin Drug Investig. 2013 Nov;33(11):809-16</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/24876549/">Pai V et al., A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V). J Diabetes Sci Technol. 2014 Jan;8(1):132-141</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/24138536/">Jani RH et al., A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther. 2014 Feb;16(2):63-71</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/26171220/">Jain MR et al., Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. Pharmacol Res Perspect. 2015 Jun;3(3):e0013</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/27187607/">Ghoghari A et al., Quantitative determination of saroglitazar, a predominantly PPAR alpha agonist, in human plasma by a LC-MS/MS method utilizing electrospray ionization in a positive mode. Biomed Chromatogr. 2016 Dec;30(12):1900-1907</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/29224415/">H Patel et al., Preclinical evaluation of Saroglitazar Magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders. Xenobiotica. 2018 Dec;48(12):1268-1277</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0146222">Deshpande A et al., A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy. PLoS One. 2016 Jan 20;11(1):e0146222</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/29022212/">Patel MR et al., Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects. Clin Drug Investig. 2018 Jan;38(1):57-65</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/29164820/">Jain MR et al., Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int. 2018 Jun;38(6):1084-1094</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.jyoungpharm.org/sites/default/files/jyp_7_1_2015_2.pdf">Arun Sharma et al., Saroglitazar, a novel cardiometabolic agent for diabetic dyslipidemia – A Review. Journal of Young Pharmacists, 2015; 7(1):2-6</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/25820046/">Shetty SR et al., Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients. Indian Heart J. 2015 Jan-Feb;67(1):23-6.</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382552/">Ramakrishnan S. From 'Make in India' to 'Made in India': the saroglitazar story. Indian Heart J. 2015 Jan-Feb;67(1):8-10.</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.practiceupdate.com/content/saroglitazar-is-a-potential-add-on-therapy-for-diabetic-dyslipidemia/40438">PracticeUpdate Editorial Team. Saroglitazar is a Potential Add-On Therapy for Diabetic Dyslipidemia. Published in Diabetes News · June 13, 2016.</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/27666920/">Sethi BK et al., Unique Interaction of Saroglitazar with Insulin. J Assoc Physicians India. 2015 Dec;63(12):95</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/27458613/">S Lam. AMERICAN DIABETES ASSOCIATION – 76TH SCIENTIFIC SESSIONS (JUNE 10-14, 2016 – NEW ORLEANS, LOUISIANA, USA). Drugs of Today 2016, 52(6): 361-366</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.sciencedirect.com/science/article/pii/S2468600X17300191">Amitesh Kumar Chatterjee. Saroglitazar may reduce the requirement of insulin dose during the treatment of diabetic dyslipidemia. IHJ Cardiovascular Case Reports (CVCR) Volume 1, Issue 3, October–December 2017, Pages 116-118.                                 </a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://medwinpublishers.com/DOIJ/DOIJ16000180.pdf">Chatterjee S, et al. Observational Study of Saroglitazar on Metabolic Parameters in Indian Patients with Diabetic Dyslipidaemia – A Fifty Eight Weeks of Clinical Experience. Diabetes Obes Int J 2018, 3(3): 000181</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://openventio.org/Volume3-Issue2/Saroglitazar-A-New-Drug-to-Treat-Diabetic-Hypertriglyceridemia-HROJ-3-135.pdf">Bhatia V, Arora P, Kaur G, Kaul U. Saroglitazar: A new drug to treat diabetic hypertriglyceridemia. Heart Res Open J. 2016; 3(2): 37-42. doi: 10.17140/HROJ-3-13</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/24944919/">Munigoti SP, Harinarayan CV. Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?. Indian J Endocr Metab 2014;18:283-7</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905264/">Manoria PC et al., The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies. Indian Heart J. 2013 Dec;65(6):683-90. doi: 10.1016/j.ihj.2013.10.015.</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="http://jcdonline.in/wp-content/uploads/2014/06/4.-Treatment-of-Hypertriglyceridemia-in-a-Diabetic-Patient-with-Renal-Impairment_Balaji-Jagamohan.pdf">Dr. Balaji Jaganmohan. Treatment of Hypertriglyceridemia in a Diabetic Patient with Renal Impairment. JOURNAL OF CLINICAL DIABETOLOGY. VOL 3 | N O . 1 | A P R - J U N E 2 0 1 6 | 1</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.hilarispublisher.com/open-access/diabetic-dyslipidemia-role-of-saroglitazar-2161-0444.1000684.pdf">Majumder A, Chatterjee S (2014) Diabetic Dyslipidemia - Role of Saroglitazar. Med chem 4: 684-687. doi:10.4172/2161-0444.100021</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://europepmc.org/article/med/25820046">Minal Mohit et al., Observational Study to Evaluate the Safety and Efficacy of Saroglitazar in Diabeticdyslipidemia Patients with and without Coronary Artery Disease (CAD). Journal of Internal Medicine of India. APRIL 2017, VOL. 11, page 7.</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843272/">Arijit Ghosh et al., Comparison of Effectiveness and Safety of Add-on Therapy of Saroglitazar and Fenofibrate with Metformin in Indian Patients with Diabetic Dyslipidaemia.  Journal of Clinical and Diagnostic Research. 2016 Mar, Vol-10(3): FC01-FC04</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403747/">Sosale A et al., Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: currentevidence. Diabetes Metab Syndr Obes. 2015 Apr 15;8:189-96.</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.sciencedirect.com/science/article/abs/pii/S0014299918300086">Durgesh Kumar et al., Saroglitazar reduces obesity and associated inflammatory consequences in murine adipose tissue, European Journal of Pharmacology, https://doi.org/10.1016/j.ejphar.2018.01.002</a></li>

<li><a rel="noopener noreferrer" href="#">Chudiwal TB, Mujeeb MMA. A novel dual PPAR-α/γ agonist, saroglitazar for the treatment of diabetic dyslipidaemia and hypertriglyceridaemia. Journal of Evolution of Research in Medical Pharmacology 2016; Vol. 2, Issue 2, July-December 2016; Page:16-19 </a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/25674933/">Joshi SR et al., Saroglitazar for the treatment of dyslipidemia in diabetic patients. Expert Opin. Pharmacother. (2015) 16(4):597-60</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.nature.com/articles/srep07706">Chatterjee S et al., Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes. Sci Rep. 2015 Jan 9;5:7706. doi: 10.1038/srep07706</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/30341861/">Bhosle D et al., Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D. J Assoc Physicians India. 2018 Mar;66(3):14-17</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/30341860/">Shah SN. The Road to Preventing Diabetes: Addressing Prediabetes and Concomitant Dyslipidemia. J Assoc Physicians India. 2018 Mar;66(3):12-1</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.longdom.org/open-access/a-prospective-multicentre-single-arm-clinical-study-to-evaluate-the-effect-of-saroglitazar-on-non-highdensity-lipoprotein-choleste-31828.html">U Kaul et al., A Prospective, Multicentric Study to Evaluate the Effects of Saroglitazar on Non-HDL Cholesterol and Small Dense LDL Particles in Patients with Diabetic Dyslipidemia. Late breaking poster session. ADA 2018. http://diabetes.diabetesjournals.org/content/67/Supplement_1/38-LB</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="file:///C:\Users\savio.fernandes\AppData\Local\Microsoft\Windows\INetCache\Content.Outlook\SXENSGJ8\Sanjay%20Chatterjee%20et%20al.,%20Real%20Time%20Clinical%20Safety%20and%20Effectiveness%20of%20Long%20Term%20Use%20of%20Saroglitazar%20in%20Indian%20Patients%20with%20Diabetic%20Dyslipidemia%20Having%20Abnormal%20%20Metabolic%20Parameters.%20J%20Diabetes%20and%20Islet%20Biology.%20Doi:%20http:\dx.doi.org\%2010.31579\%20jdib.18\003">Sanjay Chatterjee et al., Real Time Clinical Safety and Effectiveness of Long Term Use of Saroglitazar in Indian Patients with Diabetic Dyslipidemia Having Abnormal  Metabolic Parameters. J Diabetes and Islet Biology. Doi: http://dx.doi.org/ 10.31579/ jdib.18/003</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/30633968/">Poonam Giri et al., Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. Eur J Pharm Sci. 2019 Jan 8. pii: S0928-0987(19)30013-2. doi: 10.1016/j.ejps.2019.01.00</a></li>


<li><a rel="noopener noreferrer" href="#"> Dr Sayantani Bhattacharyya, Dr Supratik Bhattacharyya, Dr Kingshuk Bhattacharyya Saroglitazar and its impact on Diabetic Dyslipidemia: A Real life Observational study from Eastern India. Indian Journal of Basic and Applied Medical Research; March 2018: Vol.-7, Issue- 2, P. 298-303 </a></li>


<li><a target="_blank" rel="noopener noreferrer" href="https://www.longdom.org/open-access/a-prospective-multicentre-single-arm-clinical-study-to-evaluate-the-effect-of-saroglitazar-on-non-highdensity-lipoprotei.pdf">Kaul U, Arambam P, Kachru R, Bhatia V, Diana Y, et al. (2019) A Prospective, Multicentre, Single Arm Clinical Study to Evaluate the Effect of Saroglitazar on Non High-Density Lipoprotein Cholesterol in Patients with Diabetic Dyslipidemia Inadequately Controlled with Diet, Exercise, and Statin-The GLIDDER Study. J Diabetes Metab 10: 819. doi:10.4172/2155-6156.100081</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/30737662/">Hassan NF, Nada SA, Hassan A, El-Ansary MR, Al-Shorbagy MY, Abdelsalam RM. Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis. Inflammation. 2019 Feb 9. doi: 10.1007/s10753-019-00967-6. [Epub ahead of  print</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://cardiab.biomedcentral.com/articles/10.1186/s12933-019-0884-3">Kaul U, Parmar D, Manjunath K, Shah M, Parmar K, Patil KP, Jaiswal A. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. Cardiovasc Diabetol. 2019 Jun 17;18(1):80. doi: 10.1186/s12933-019-0884-3.</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/31367862/">Mirhan N. Makled1 &amp; Maha H. Sharawy1 &amp; Mohammed S. El-Awady1The dual PPAR-α/γ agonist saroglitazar ameliorates thioacetamide-induced liver fibrosis in rats through regulating leptin. Naunyn Schmiedebergs Arch Pharmacol. 2019 Jul 31. doi: 10.1007/s00210-019-01703-5. [Epub ahead of print</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="http://www.ijdonline.com/issues/1.pdf">Mathur R, Jhaveri K. Saroglitazar may Reduce the Dose of Other Antidiabetic Medications During the Treatment of Diabetic Dyslipidemia. Int J Diab July 2019;1-</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/31886093/">Roy S, Ghosh A. Significant Reduction of Elevated Triglycerides and Liver Fibrosis in Diabetic Dyslipidemia with Saroglitazar: A Case Report. Cureus. 2019 Dec 12;11(12):e6361. doi: 10.7759/cureus.6361.</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.nature.com/articles/s41598-019-55466-3">Jain N, Bhansali S, Kurpad AV, Hawkins M, Sharma A, Kaur S, Rastogi A, Bhansali A. Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial. Sci Rep. 2019 Dec 12;9(1):19017. doi: 10.1038/s41598-019-55466-3</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.hindawi.com/journals/crim/2020/4287075/">Roy S. Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4 mg: An Indian Experience. Case Rep Med. 2020;2020:4287075. Published 2020 Mar 27. doi:10.1155/2020/428707</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.unboundmedicine.com/medline/citation/32030508/Abrogation_of_postprandial_triglyceridemia_with_dual_PPAR_%CE%B1/%CE%B3_agonist_in_type_2_diabetes_mellitus:_a_randomized,_placebo-controlled_study.">Rastogi A, Dunbar RL, Thacker HP, Bhatt J, Parmar K, Parmar DV. Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study. Acta Diabetol. 2020;57(7):809-818. doi:10.1007/s00592-020-01487-</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/31979903/">Goyal P, Goyal O, Chhina RS. Saroglitazar Improves Transaminases and Elastography in Patients with Diabetic Dyslipidemia and Non-Alcoholic Fatty Liver Disease. J Assoc Physicians India. 2020;68(1):97</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.ijcmr.com/uploads/7/7/4/6/77464738/ijcmr_2702.pdf">Jaswant Goyal, Sudhir Bhandari, Sengupta Kushan Kaushik, Barkha Goyal, Saloni Chandalia, Rashmi Attri. A study to evaluate the effect of saroglitazar in type 2 diabetes. International Journal of Contemporary Medical Research 2019;6(9):I1-I4</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://cardiab.biomedcentral.com/articles/10.1186/s12933-020-01073-w">Krishnappa, M., Patil, K., Parmar, K. et al. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study). Cardiovasc Diabetol 19, 93 (202</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.cureus.com/articles/34795-an-observational-study-of-reduction-in-glycemic-parameters-and-liver-stiffness-by-saroglitazar-4-mg-in-patients-with-type-2-diabetes-mellitus-and-nonalcoholic-fatty-liver-disease">Mitra A (July 08, 2020) An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Cureus 12(7): e9065. DOI 10.7759/cureus.906</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.nature.com/articles/s41598-020-78342-x">Goyal O, Nohria S, Goyal P, Kaur J, Sharma S, Sood A, Chhina RS. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Sci Rep. 2020 Dec 3;10(1):21117. doi: 10.1038/s41598-020-78342-x. PMID: 33273703; PMCID: PMC7713236</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.nature.com/articles/s41598-020-66458-z#Sec2">Kumar DP, Caffrey R, Marioneaux J, et al. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. Sci Rep. 2020;10(1):9330. Published 2020 Jun 9. doi:10.1038/s41598-020-66458-</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.21203/rs.3.rs-123364/v1">Manjunath K et al. Effectiveness of The PPAR Agonist Saroglitazar in Nonalcoholic Steatohepatitis: Positive Data from Preclinical &amp; Clinical Studies. BMC Gastroenterology.</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/33152542/">Siddiqui MS, Idowu MO, Parmar D, Borg BB, Denham D, Loo NM, Lazas D, Younes Z, Sanyal AJ, A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients with Nonalcoholic Steatohepatitis, Clinical Gastroenterology and Hepatology (2020), doi: https:// doi.org/10.1016/j.cgh.2020.10.051</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.ijcmr.com/uploads/7/7/4/6/77464738/ijcmr_2873.pdf">Santosh D Hajare, Varadaraj P Gokak, Sandesha Ghorpade, Amar Patil, Arvind Jadhav. An investigator initiated prospective, single arm observational study to evaluate the safety and efficacy of saroglitazar 4 mg in patients with non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH). International Journal of Contemporary Medical Research 2019;6(12):L5-L7</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://pubmed.ncbi.nlm.nih.gov/31889755/">Choudhary et al., Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease, Journal of Clinical and Experimental Hepatology,</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://www.xiahepublishing.com/2310-8819/JCTH-2020-00055">Mithun Sharma et al. Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. Journal of Clinical and Translational Hepatology. DOI: 10.14218/JCTH.2020.0005</a></li>
<li><a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1016/j.jceh.2019.06.003">Kothari S, Dhami-Shah H, Shah SR, Anti-diabetic Drugs and Statins in NAFLD, Journal of Clinical and Experimental Hepatology,</a></li>


                            <!-- <li><a target="_blank"  rel="noopener noreferrer"  href="http://www.nature.com/srep/2015/150109/srep07706/full/srep07706.html">Observational Study of effects of Saroglitazar on Glycaemic and Lipid Parameters on Indian Patients with Type 2 Diabetes</a></li>
                            <li><a target="_blank"  rel="noopener noreferrer" href="http://www.sciencedirect.com/science/article/pii/S0019483215000115?np=y#">Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients</a></li>
                            <li><a target="_blank"  rel="noopener noreferrer" href="http://online.liebertpub.com/doi/abs/10.1089/dia.2013.0253">Lipaglyn™ Saroglitazar Phase III Press VI</a></li>
                            <li><a target="_blank"  rel="noopener noreferrer" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390522">Lipaglyn™ Saroglitazar Phase III Press V</a></li>
                            <li><a target="_blank"  rel="noopener noreferrer" href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0146222">Lipaglyn™ Saroglitazar Phase II Lipodystrophy PLOS ONE Publication</a></li>
                            <li><a target="_blank"  rel="noopener noreferrer" href="http://link.springer.com/article/10.1007%2Fs40261-013-0128-3">Saroglitazar - Phase-I Publication</a></li>
                            <li><a target="_blank"  rel="noopener noreferrer" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492752">Saroglitazar-Preclinical Publication-PRP- June -2015</a></li>
                            <li><a target="_blank"  rel="noopener noreferrer" href="https://cardiab.biomedcentral.com/articles/10.1186/s12933-019-0884-3">New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non alcoholic fatty liver disease: integrated analysis of the real world evidence</a></li> -->
                        </ul>

                        <h3>POSTERS AND PRESENTATIONS :</h3>
                        <ul class="ulArrow" id="lidecimal">
						
						<li><a href="https://www.aasld.org/sites/default/files/2021-11/TLM%202021%20Late%20Breaking%20Abstracts%2011.01.21.pdf" target="_blank" rel="noopener noreferrer">American Association for the Study of Liver Diseases (AASLD): THE LIVER MEETING 2021. Nov 12-15</a></li>

                            <li><a href="https://engage.aasld.org/events/event-description?CalendarEventKey=2f9c87d2-1ad0-4ef1-b50e-0287a5f21342&amp;Home=%2Fevents%2Fcalendar" target="_blank" rel="noopener noreferrer">American Association for the Study of Liver Diseases (AASLD): THE LIVER MEETING 2020. Nov 13-16</a></li>

                            <li><a href="https://www.aasld.org/sites/default/files/2019-10/2019-TLM-LateBreakingAbstracts.pdf" target="_blank" rel="noopener noreferrer">American Association for the Study of Liver Diseases (AASLD) 2019. Nov 8-12, Boston.</a></li>

                            <li><a href="https://www.zyduslife.com/public/pdf/research/Zydus-Poster-EASL-2018-final.pdf" target="_blank" rel="noopener noreferrer">Saroglitazar Attenuates Hepatic Inflammation, Oxidative Stress and Fibrosis in Models of NAFLD/NASH (Poster #1619, 2016 AASLD Liver Meeting in Boston, USA)</a></li>
                            <li><a href="javascript:;" target="_blank" rel="noopener noreferrer">One Year Post Marketing Surveillance Study of Saroglitazar in Patient with Diabetic Dyslipidemia (Late Breaking Abstract #37-LB, 76th Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, Louisiana, USA)</a></li>
                            <li><a href="javascript:;" target="_blank" rel="noopener noreferrer">Efficacy and Safety of Saroglitazar in Indian Diabetics- Twoyear Data (Late Breaking Abstract #40-LB, 76th Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, Louisiana, USA) </a></li>
                            <li><a href="javascript:;" target="_blank" rel="noopener noreferrer">Antidiabetic Efficacy of Saroglitazar and Its Combinations with Other Drugs in db/db Mice (Abstract #1111-P, 76th Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, Louisiana, USA)</a></li>
                            <li><a href="javascript:;" target="_blank" rel="noopener noreferrer">Study of Saroglitazar in Treatment of Prediabetes with Dyslipidemia (Abstract #1133-P, 76th Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, Louisiana, USA) </a></li>
                            <li><a href="javascript:;" target="_blank" rel="noopener noreferrer">Efficacy of dapagliflozin-saroglitazar combination for the treatment of NAFLD in young diabetics (Abstract #73-OR, 76th Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, Louisiana, USA) </a></li>
                            <li><a href="javascript:;" target="_blank" rel="noopener noreferrer">Effect of Saroglitazar on Metabolic Parameters in Indian Patients with Diabetic Dyslipidemia - A 40 week, Retrospective Analysis (Abstract #2182-PUB, 76th Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, Louisiana, USA) </a></li>
                            <li><a href="http://www.abstractsonline.com/pp8/#!/4008/presentation/41899" target="_blank" rel="noopener noreferrer">Effect of Saroglitazar on non HDL-c in Diabetic Dyslipidemia (Abstract #2269-PUB, 76th Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, Louisiana, USA) </a></li>
                           <li><a href="https://www.zyduslife.com/public/pdf/research/Saroglitazar-In-Non-Alcoholic-Fatty-Liver-Disease.pdf" target="_blank" rel="noopener noreferrer">Saroglitazar In Non-Alcoholic Fatty Liver Disease (Poster #842, The American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific and Clinical Congress in Orlando, Florida, USA)</a></li>
                            <li><a href="https://www.zyduslife.com/public/pdf/research/Novel-Action-Of-Saroglitazar-In-Patients-With-Diabetic-Dyslipidemia-An-Observational-Study.pdf" target="_blank" rel="noopener noreferrer">Novel Action Of Saroglitazar In Patients With Diabetic Dyslipidemia – An Observational Study (Poster #1311, The American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific and Clinical Congress in Orlando, Florida, USA)</a></li>
                            <li><a href="javascript:;" target="_blank" rel="noopener noreferrer">Lipid Lowering Effects of Saroglitazar in Preclinical Models: Potential Synergistic Interaction with Statins. (Abstract #693-P, 75th Annual Scientific Sessions of the American Diabetes Association (ADA) in Boston, Massachusetts, USA)</a></li>
                            <li><a href="javascript:;" target="_blank" rel="noopener noreferrer">Saroglitazar Shows Beneficial Effects on Insulin Sensitivity, Dyslipidemia, and Blood Pressure in Zucker Fatty Rats. (Abstract #703 -P, 75th Annual Scientific Sessions of the American Diabetes Association (ADA) in Boston, Massachusetts, USA)</a></li>
                            <li><a href="javascript:;" target="_blank" rel="noopener noreferrer">Effect of Saroglitazar, a Dual PPAR-a/γ agonist, on Lipid and Glycemic Parameters in Indian Patients with Diabetic Dyslipidemia—A 27-Week, Retrospective Analysis. (Abstract #704-P, 75th Annual Scientific Sessions of the American Diabetes Association (ADA) in Boston, Massachusetts, USA)</a></li>
                            <li><a href="javascript:;" target="_blank" rel="noopener noreferrer">To Assess the Effect of 4mg Saroglitazar on Patients of Diabetes Dyslipidemia with Nonalcoholic Fatty Liver Disease for 24 Weeks at Diabetes Care Centre. (Abstract #712-P, 75th Annual Scientific Sessions of the American Diabetes Association (ADA) in Boston, Massachusetts, USA)</a></li>
                            <li><a href="https://www.zyduslife.com/public/pdf/research/Effect-of-Saroglitazar-on-Fatty-Acid-Metabolism-in-Zucker-FaFa-Rats.pdf" target="_blank" rel="noopener noreferrer">Effect of Saroglitazar on Fatty Acid Metabolism in Zucker Fa/Fa Rats (Abstract #1187-P, 75th Annual Scientific Sessions of the American Diabetes Association (ADA) in Boston, Massachusetts, USA)</a></li>
                            <li><a href="javascript:;" target="_blank" rel="noopener noreferrer">Saroglitazar Shows Therapeutic Benefits in Mouse Model of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) (Abstract #1957-P, 75th Annual Scientific Sessions of the American Diabetes Association (ADA) in Boston, Massachusetts, USA)</a></li>
                            <li><a href="https://www.zyduslife.com/public/pdf/research/Saroglitazar-in-Diabetic-Dyslipidemia-1-Year-Data.pdf" target="_blank" rel="noopener noreferrer">Saroglitazar in Diabetic Dyslipidemia: 1 year data (Abstract #126-LB, 75th Annual Scientific Sessions of the American Diabetes Association (ADA) in Boston, Massachusetts, USA)</a>
                                <a href="javascript:;">9-month safety and efficacy of Saroglitazar in Diabetic Dyslipidemia (Abstract #1233, American Association of Clinical Endocrinologists 24th Annual Scientific and Clinical Congress in Nashville, TN, USA)</a></li>
                            <li><a href="javascript:;">Lipaglyn™ Presentation (2015 Keystone Symposia Conference on Liver Metabolism and Nonalcoholic Fatty Liver Disease (NAFLD) in British Columbia, Canada)</a></li>
                            <li><a href="javascript:;" target="_blank" rel="noopener noreferrer">Efficacy of Saroglitazar, a Novel PPAR a/y Agonist in a mouse model of non-alcoholic steatohepatitis. (Poster #2011, 2015 Keystone Symposia Conference on Liver Metabolism and Nonalcoholic Fatty Liver Disease (NAFLD) in British Columbia, Canada)</a></li>
                        </ul>


                    </div>

                </div>
            </div>
        </div>
        <div class="panel panel-default">
            <div class="panel-heading">
                <h4 class="panel-title">
                    <a data-toggle="collapse" data-parent="#accordion" href="#collapse2">Desidustat - Oral HIF-PH Inhibitor for Treating Anemia
                        <i class="more-less glyphicon glyphicon-plus"></i></a>
                </h4>
            </div>
            <div id="collapse2" class="panel-collapse collapse">
                <div class="panel-body">
                    <div class="custom-table table-responsive zyan1">
                        <table class="table">
                            <tbody>
                            <!-- <tr>
                                <td><h6>Indication</h6></td>
                                <td><img src="https://www.zyduslife.com/public/images/indication.jpg" class="img-responsive"  alt="indication"></td>
                            </tr> -->
                            <tr>
                                <td><h6>Current Status</h6></td>
                                <td class="tbodystatus">

                                    <table>
                                        <tbody><tr>
                                            <td>Approved (India)</td>
                                            <td>Anemia in CKD</td>
                                        </tr>
                                        <tr>
                                            <td>Phase III (China)</td>
                                            <td>Anemia in CKD</td>
                                        </tr>
                                        <tr>
                                            <td>Phase I (USA)</td>
                                            <td>Chemotherapy Induced Anemia (CIA)</td>
                                        </tr>
                                    </tbody></table>

                                   <!--  <span class="wid" style="margin-right: 20px;"> NDA (India) </span><span class="pad25"> Anemia in CKD </span> <br>
                                    <span class="wid"> Phase III (China) </span><span class="pad25"> Anemia in CKD </span>
                                    <span class="wid"> Phase I (USA) </span><span class="pad25"> Chemotherapy Induced Anemia (CIA) </span> -->
                                </td>
                                <!-- <td>
                                    <p>
                                        NDA <span class="pad25"> Anemia in CKD </span> <br>
                                        Phase I <span class="pad25"> Chemotherapy Induced Anemia (CIA) </span>
                                    </p>
                                </td> -->
                            </tr>
                            <tr>
                                <td><h6>Unmet Need</h6>
                                    <h6></h6></td>
                                <td>Anemia is a condition of having lower red blood cells or lower hemoglobin levels than is normal. Anemia is a serious medical condition linked to increased morbidity and mortality, and is commonly observed in patients with chronic kidney disease (CKD). Currently available agents for the treatment of anemia include injectable EPO stimulating agents (ESA’s) and intravenous iron supplements. The estimated global market for treatments for anemia related to CKD is $ 10 billion.</td>
                            </tr>
                            <tr>
                                <td><h6>Publications &amp; Posters</h6></td>
                                <td>
                                    
                                    <a href="https://www.karger.com/Article/Pdf/523961" target="_blank" rel="noopener noreferrer">1. Desidustat in Anemia due to Non- Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND). Am J Nephrol. 2022. DOI: 10.1159/000523961</a><br><br>
<a href="https://www.karger.com/Article/FullText/523949" target="_blank" rel="noopener noreferrer">2. Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D). Am J Nephrol. 2022. DOI: 10.1159/000523949</a><br><br>
<a href="https://www.sciencedirect.com/science/article/pii/S2590257122000220?via%3Dihub" target="_blank" rel="noopener noreferrer">3. Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state. Current Research in Pharmacology and Drug Discovery. 2022; 100102. https://doi.org/10.1016/j.crphar.2022.100102. </a><br><br>
<a href="https://www.karger.com/Article/Abstract/500232" target="_blank" rel="noopener noreferrer">4. Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study. Am J Nephrol. 2019;49:470–478.</a><br><br>
<a href="https://pubmed.ncbi.nlm.nih.gov/28508936/" target="_blank" rel="noopener noreferrer">5. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers. Clin Pharmacokinet. 2018 Jan; 57(1):87-102.</a><br><br>
<a href="https://pubmed.ncbi.nlm.nih.gov/26367279/" target="_blank" rel="noopener noreferrer">6. Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Drug Res (Stuttg). 2016 Feb; 66(2):107-12.</a><br><br>
<a href="https://pubmed.ncbi.nlm.nih.gov/28042744/" target="_blank" rel="noopener noreferrer">7. Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia. Xenobiotica. 2018 Jan; 48(1):37-44.</a><br><br>
<a href="https://pubmed.ncbi.nlm.nih.gov/28488896/" target="_blank" rel="noopener noreferrer">8. A sensitive assay for ZYAN1 in human whole blood and urine utilizing positive LC-MS/MS electrospray ionization. Bioanalysis. 2017 May; 9(9):719-732.</a><br><br>
<a href="https://pubmed.ncbi.nlm.nih.gov/30458168/" target="_blank" rel="noopener noreferrer">9. Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation. Eur J Pharmacol. 2019 Jan 15; 843:113-120.</a><br><br>
<a href="https://pubmed.ncbi.nlm.nih.gov/29712435/" target="_blank" rel="noopener noreferrer">10. Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. J Med Chem. 2018 Aug 23; 61(16):6964-6982.</a><br><br>
<a href="https://pubmed.ncbi.nlm.nih.gov/33480036/" target="_blank" rel="noopener noreferrer">11. Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress. Drug Dev Res. 2021; 1–9.</a><br><br>
<a href="https://link.springer.com/article/10.1007/s13318-022-00788-3" target="_blank" rel="noopener noreferrer">12. Nonclinical Pharmacokinetic Evaluation of Desidustat: a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia, European Journal of Drug Metabolism and Pharmacokinetics. 2022 Jul 26. doi: 10.1007/s13318-022-00788-3</a><br><br>                             
                                </td>
                            </tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </div>
        </div>
        <div class="panel panel-default">
            <div class="panel-heading">
                <h4 class="panel-title">
                    <a data-toggle="collapse" data-parent="#accordion" href="#collapse4">ZYIL1: Novel Oral Small Molecule NLRP3 inhibitor 

                        <i class="more-less glyphicon glyphicon-plus"></i></a>
                </h4>
            </div>
            <div id="collapse4" class="panel-collapse collapse">
                <div class="panel-body">
                    <!--<img src="https://www.zyduslife.com/public/images/nce-pipline-q2-2020.jpg" class="img-responsive" alt="NCE Pipeline"/>-->
                    <div class="custom-table table-responsive zyan1">
                        <table class="table">
                            <tbody>
                            <tr>
                                <td><h6>Potential Indication </h6></td>
                                <td><img src="https://www.zyduslife.com/public/images/indication_zyil.jpg" class="img-responsive" alt="indication"></td>
                            </tr>
                            <tr>
                                <td><h6>Current Status</h6></td>
                                <td> <span class="wid"> Phase II(a) </span> <span class="pad25"> Cryopyrin-Associated Periodic Syndrome (CAPS)</span></td>
                            </tr>
                            <tr>
                                <td><h6>Unmet Need</h6>
                                    <h6></h6></td>
                                <td>NLRP3 inflammasomes are involved in the inflammation process by production and release of proinflammatory cytokines IL-1β and IL-18. This harmful inflammation within the body leads to the onset and development of various kinds of diseases, including Acute Respiratory Distress Syndrome (ARDS), auto-immune diseases, inflammatory diseases, cardiovascular diseases, metabolic disorders, Gastro-intestinal diseases (inflammatory bowel disease), renal diseases and CNS diseases. Currently most of the inflammatory disease are mainly treated by several approved biological drugs. A novel oral small molecule NLRP3 inhibitor like ZYIL1 with good safety profile has the potential to be the new standard of care for several inflammatory disease.</td>
                            </tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </div>
        </div>
        <div class="panel panel-default">
            <div class="panel-heading">
                <h4 class="panel-title">
                    <a data-toggle="collapse" data-parent="#accordion" href="#collapse3">New Molecular Entities in Development
                        <i class="more-less glyphicon glyphicon-plus"></i></a>
                </h4>
            </div>
            <div id="collapse3" class="panel-collapse collapse">
                <div class="panel-body">
                    <!--<img src="https://www.zyduslife.com/public/images/nce-pipline-q2-2020.jpg" class="img-responsive" alt="NCE Pipeline"/>-->

                </div>
            </div>
        </div>
    </div>




    <div class="imageTextSlider biologicsSlider">
        <div class="owl-carousel owl-theme owl-loaded">
            
        <div class="owl-stage-outer"><div class="owl-stage" style="transform: translate3d(0px, 0px, 0px); transition: all 0s ease 0s; width: 1140px;"><div class="owl-item active" style="width: 1140px;"><div class="item">
                <div class="col-md-8"><a href="http://lipaglyn.com/" target="_blank" rel="noopener noreferrer">
                        <img src="https://www.zyduslife.com/public/images/innovation-1.jpg" alt="Innovation"></a></div>
                <div class="textBox">
                    <!-- <h4><a class="innovation" href="http://www.lipaglyn.com/" target="_blank">Lipaglyn - Novel drug to treat diabetic dyslipidemia, a global, unmet healthcare need</a></h4> -->
                    <h4><a class="innovation" href="http://www.lipaglyn.com/" target="_blank">BILYPSA – Novel drug to treat Non Alcoholic Fatty Liver Disease with comorbidities and Non Alcoholic Steatohepatitis</a></h4>
                    <p>The first drug to get approval for NAFLD &amp; NASH anywhere in the world , an NCE from an Indian research pipeline to move from the lab to the market.</p>
                </div>
            </div></div></div></div><div class="owl-nav disabled"><div class="owl-prev">prev</div><div class="owl-next">next</div></div><div class="owl-dots disabled"><div class="owl-dot active"><span></span></div></div></div>
    </div>

    <h2>BIOLOGICS <span id="biologics" class="idName"></span></h2>
     <div class="panel-group accordion" id="accordion2">
        <div class="panel panel-default">
            <div class="panel-heading">
                <h4 class="panel-title">
                    <a data-toggle="collapse" data-parent="#accordion2" href="#collapse02">Biologics Pipeline
                        <i class="more-less glyphicon glyphicon-plus"></i></a>
                </h4>
            </div>
            <div id="collapse02" class="panel-collapse collapse">
                <div class="panel-body">
                    <!--<img src="https://www.zyduslife.com/public/images/Biologics-Pipeline-q2-2020.jpg" class="img-responsive" alt="Biologics Pipeline"/>-->
                </div>
            </div>
        </div>

       <!-- <div class="panel panel-default">
            <div class="panel-heading">
                <h4 class="panel-title">
                    <a data-toggle="collapse" data-parent="#accordion2" href="#collapse01">Biosimilar Pipeline
                        <i class="more-less glyphicon glyphicon-plus"></i></a>
                </h4>
            </div>
            <div id="collapse01" class="panel-collapse collapse">
                <div class="panel-body">
                    <img src="https://www.zyduslife.com/public/images/Zydus_ResearchPipeline_Biosimilar_Pipeline.png" class="img-responsive" alt=""/>
                </div>
            </div>
        </div>-->
    </div>



    <div class="imageTextSlider biologicsSlider">
        <div class="owl-carousel owl-theme owl-loaded">
            
        <div class="owl-stage-outer"><div class="owl-stage" style="transform: translate3d(0px, 0px, 0px); transition: all 0s ease 0s; width: 1140px;"><div class="owl-item active" style="width: 1140px;"><div class="item">
                <div class="col-md-8"><a href="https://exemptia.com/" target="_blank" rel="noopener noreferrer"><img src="https://www.zyduslife.com/public/images/innovation-2.jpg" alt="Adalimumab"></a></div>
                <div class="textBox">
                    <h4><a class="innovation" href="https://exemptia.com/" target="_blank">Exemptia: World's first biosimilar of Adalimumab</a></h4>
                    <p>Provides a new lease of life to Indian patients of inflammatory arthritis, who did not have access to this revolutionary therapy, so far.</p>
                </div>
            </div></div></div></div><div class="owl-nav disabled"><div class="owl-prev">prev</div><div class="owl-next">next</div></div><div class="owl-dots disabled"><div class="owl-dot active"><span></span></div></div></div>
    </div>




    
    <h2>Twinrab<sup>TM</sup><span id="Twinrab" class="idName"></span></h2>
    <div class="panel-group accordion" id="accordion4">
        <div class="panel panel-default">
            <div class="panel-heading">
                <h4 class="panel-title">
                    <a data-toggle="collapse" data-parent="#accordion4" href="#collapse04">Twinrab<sup>TM</sup>: World First Novel Cocktail of Rabies monoclonal antibodies
                        <i class="more-less glyphicon glyphicon-plus"></i></a>
                </h4>
            </div>
            <div id="collapse04" class="panel-collapse collapse">
                 <div class="panel-body">
                    <div class="col-md-12">
                        <h3>Rabies and its Prevalence</h3>
                        <ul class="ulArrow cf">
                            <li>Rabies is an acute viral encephalomyelitis of humans and other warm-blooded vertebrates<sup>1</sup></li>
                            <li>It is caused by a member of the genus Lyssavirus of the Rhabdoviridae family<sup>1</sup></li>
                            <li>Rabies is almost always fatal, as it has one of the highest case fatality rates of any infectious disease<sup>2</sup></li>
                            <li>In more than 99% of all cases of human rabies, the virus is transmitted from dogs<sup>2</sup></li>
                            <li>Globally around 59,000 human rabies deaths occur every year of which about one-third – 20,000, occurs in India alone<sup>3</sup></li>
                            <li>Globally, around 6 million people undergo post exposure treatment (PET) of rabies every year<sup>4</sup></li>
                            <li>In India, around 17.4 million animal bites occur every year, among which only 5 million rabies undergo post exposure prophylaxis (PEP) are provided<sup>3</sup></li>
                        </ul>
                        <h3>Post-exposure Prophylaxis</h3>
                        <p>All the cases of rabies exposure should be treated immediately for the prevention of of clinical symptoms and death.</p>
                        <p>Post-exposure prophylaxis consists of:</p>
                        <ul class="ulArrow cf">
                            <li>Wound treatment</li>
                            <li>Administration of rabies vaccines based on WHO recommendations</li>
                            <li>Administration of rabies immunoglobulin (if indicated)</li>
                        </ul>
                        <p> <img src="https://www.zyduslife.com/public/images/twinrab_1.jpg" class="img-responsive marginAuto" alt="Zydus Twinrab"></p>
                        <!--<p>Lipaglyn™ (Saroglitazar Mg) currently approved in India is a prescription medicine for the treatment of Hypertriglyceridemia and Diabetic Dyslipidemia in Patients with Type 2 Diabetes not controlled by statins. The recommended dose of Lipaglyn™ is 4 mg once-a-day.</p>-->
                        <h3>Passive Immunisation<sup>6</sup></h3>
                        <ul class="ulArrow cf">
                            <li>Passive immunization should be administered just before or shortly after administration of the first dose of vaccine given in the post-exposure prophylaxis regimen</li>
                            <li>If it is not immediately available, passive immunization can be administered up until the seventh day after initiation of the primary series of post-exposure prophylaxis (with cell-culture or embryonated-egg rabies vaccine)</li>
                            <li>Passive immunization should be administered just before or shortly after administration of the first dose of vaccine given in the post-exposure prophylaxis regimen</li>
                            <li>If it is not immediately available, passive immunization can be administered up until the seventh day after initiation of the primary series of post-exposure prophylaxis (with cell-culture or embryonated-egg rabies vaccine)</li>
                        </ul>
                        <h3>Unmet Need – Requirement of Anti-Rabies Monoclonal Antibodies</h3>
                        <p>Although two types of RIGs (HRIGs and ERIGs) are available, they have the following drawbacks:</p>
                        <p><strong>1. HRIG:<sup>1</sup></strong></p>
                        <ul class="ulArrow cf">
                            <li>Risk of infections</li>
                            <li>Very expensive and available in limited quantities</li>
                            <li>High Volume of Administration</li>
                        </ul>
                        <p><strong>2. ERIG:<sup>1</sup></strong></p>
                        <ul class="ulArrow cf">
                            <li>Risk of zoonotic infections</li>
                            <li>Production largely discontinued due to animal protection groups</li>
                            <li>High Volume of Administration<sup>7</sup></li>
                        </ul>
                        <p><strong>Other limitations of HRIG and ERIG7</strong></p>
                        <ul class="ulArrow cf">
                            <li>1.	High cost – &lt;2% utilization world-wide</li>
                            <li>2.	Cold storage</li>
                            <li>3.	Potential shortages</li>
                            <li>4.	Potential blood borne pathogens – Virus inactivation steps required</li>
                        </ul>
                        <h3>Twinrab<sup>TM</sup> - World‘s First Anti-Rabies Monoclonal Antibody Cocktail</h3>
                        <p>Twinrab<sup>TM</sup> is a cocktail of two anti-rabies monoclonal antibodies, indicated for the post-exposure prophylaxis (PEP) of contact with a rabid or suspected rabid animal.</p>
                        <p>Twinrab™ is an equipotent mixture of two monoclonal antibodies i.e. docaravimab (MAb 62-71-3) and miromavimab (MAb M777-16-3) binding to two distinct sites on the Rabies virus.</p>
                        <p>The hybridomas were sourced from the following WHO collaborating centres through NIBSC, United Kingdom:</p>
                        <ul class="ulArrow cf">
                            <li>Docaravimab (MAb 62-71-3) – Centres for Disease Control and Prevention (CDC), Atlanta, USA</li>
                            <li>Miromavimab (MAb M777-16-3) – Animal Diseases Research Institute (ADRI), Nepean, Canada</li>
                        </ul>
                        <p>The individual monoclonal antibodies present in the Twinrab™ cocktail mixture were found to neutralize in vitro, various rabies and rabies related viruses such as (CVS 11, SAD B19, PV, Kelev, European Fox, Dog Turkey, Dog Ethiopia, Dog India, Dog Mexico, Wolf Sarajevo, Bobcat-USA, EBLV 1, EBLV 2, East European fox, Polar fox, Dog Azerbaijan, Dog Nepal).</p>
                        <p>In various in vivo studies, the antibody cocktail was found to neutralize rabies virus isolates (CVS11, Mexican (2004), Thai (2006), Indian (2008) canine variants and Texas Fox 393 rabies virus). In still another in vivo study, the cocktail was also found to neutralize rabies virus isolates from Dog, Canine, Human, and Bovine sources isolated from southern parts of India.</p>
                        <h3>Twinrab<sup>TM</sup> – Bridging the unmet needs</h3>
                        <ul class="ulArrow cf">
                            <li>Twinrab™ is a novel drug for rabies post-exposure prophylaxis (PEP), approved by DCGI</li>
                            <li>Twinrab™ received orphan drug designation from US FDA in May 2019</li>
                            <li>Twinrab™ is World's First Novel Cocktail of 2 mAbs binding to two distinct epitopes, Docaravimab: Site I or III and Miromavimab: Site II</li>
                            <li>Cell lines in Twinrab™ have been sourced from WHO collaborating centres</li>
                            <li>Twinrab™ ensures more protective titre at the site of bite</li>
                            <li>Twinrab™ neutralizes a wide variety of viruses</li>
                            <li>There is no risk of zoonotic infection</li>
                            <li>There is no skin sensitivity test required</li>
                            <li>Twinrab™ has reduced amount of proteins and high purity that ensures less adverse events</li>
                        </ul>
                        <h3>Therapeutic indication</h3>
                        <p>Twinrab<sup>TM</sup> is indicated for post exposure prophylaxis in individuals with suspected rabies exposure. Twinrab™ must always be used in combination with Rabies vaccine as part of post exposure prophylaxis in line with the recommendation of World Health Organization (WHO).</p>
                        <h3>Dose and Mode of Administration</h3>
                        <p>The recommended dose of Twinrab<sup>TM</sup> is 40 IU per kg of body weight. Twinrab<sup>TM</sup> is administered through infiltration around the wounds / scratches and by intramuscular injection.The entire Twinrab™ dose, or as much as anatomically possible (avoiding possible compartment syndrome), should be infiltrated carefully into or as close as possible to the wound(s) or exposure sites.</p>
                        <h3>References:</h3>
                        <ul class="ulArrow cf num">
                            <li>RabiMabs: A novel monoclonal antibody cocktail for post-bite prophylaxis against Rabies virus. U.S. Food and Drug Administration. <a href="https://www.fda.gov/media/106517/download" target="_blank">https://www.fda.gov/media/106517/download.</a> Accessed November 18, 2019.</li>
                            <li>WHO. WHO Expert Consultation on Rabies, Second report. In: WHO Technical Report Series 982. Geneva: World Health Organization; 2013. <a href="http://apps.who.int/iris/bitstream/10665/85346/1/9789240690943_eng" target="_blank">http://apps.who.int/iris/bitstream/10665/85346/1/9789240690943_eng.pd</a></li>
                            <li>Sudarshan MK, Narayana DH, Jayakrishnappa MB. Market mapping and landscape analysis of human rabies biologicals in India. Indian J Public Health. 2019;63(Suppl S1):37-43.</li>
                            <li>Mohammad K, Gupta P. A study of human rabies cases admitted in infectious disease hospital KGMU, Lucknow, North India. Int J Community Med Public Health. 2018;5:4795-8.</li>
                            <li>Treatment. Rabies. WHO <a href="https://www.who.int/rabies/about/home_treatment/en/" target="_blank">https://www.who.int/rabies/about/home_treatment/en/</a>. Accessed November 28, 2019.</li>
                            <li>Rabies. WHO. Available at: <a href="https://www.who.int/ith/vaccines/rabies/en/" target="_blank">https://www.who.int/ith/vaccines/rabies/en/</a>. Accessed November 28, 2019.</li>
                            <li>Background on Rabies and Why Monoclonal Antibodies (mAbs) are Being Developed for Rabies PEP. U.S. Food and Drug Administration. <a href="https://www.fda.gov/media/125085/download" target="_blank">https://www.fda.gov/media/125085/download</a>. Accessed December 06, 2019.</li>
                        </ul>
                    </div>

                </div>
            </div>
        </div>

       
    </div>

    <div class="imageTextSlider biologicsSlider">
        <div class="owl-carousel owl-theme owl-loaded">
            
        <div class="owl-stage-outer"><div class="owl-stage" style="transform: translate3d(0px, 0px, 0px); transition: all 0s ease 0s; width: 1140px;"><div class="owl-item active" style="width: 1140px;"><div class="item">
                <div class="col-md-8"><a href="https://twinrab.com/" target="_blank"><img src="https://www.zyduslife.com/public/images/innovation-4.jpg" alt="Tablets"></a></div>
                <a class="innovation" href="https://twinrab.com/" target="_blank">
                <div class="textBox">
                    <h4>Twinrab<sup>TM</sup> : A Breakthrough innovation in rabies PEP</h4>
                    <p>World’s First Novel Rabies Monoclonal Antibodies (mAbs) cocktail containing Docaravimab and Miromavimab, providing dual protection against rabies.</p>
                </div>
                </a>
            </div></div></div></div><div class="owl-nav disabled"><div class="owl-prev">prev</div><div class="owl-next">next</div></div><div class="owl-dots disabled"><div class="owl-dot active"><span></span></div></div></div>
    </div>

    

    <h2>VACCINES <span id="vaccines" class="idName"></span></h2>
    <p>The Vaccine Technology Centre (VTC) is the vaccine research centre of the Zydus Group. VTC has two state-of-the-art R &amp; D Centers, one located in Catania, Italy and the other in Ahmedabad, in the western part of India. The Vaccine Technology Centre (VTC) has been developing vaccines for the basic vaccine programmes such as Diphtheria, Pertussis, Tetanus, Haemophilus Influenzae type B, Hepatitis B, Measles, Mumps, Rubella, Varicella, Influenza and Typhoid fever. In addition, VTC is developing new vaccines such as Human Papilloma Virus, Leishmaniasis, Malaria, Haemorrhagic Congo Fever, Ebola and Japanese Encephalitis.</p>
    <p>Zydus has indigenously developed, manufactured and launched India's first Tetravalent Inactivated Influenza vaccine, VaxiFlu – 4. The vaccine provides protection from the four influenza viruses- H1N1, H3N2, Type B (Brisbane) and Type B (Phuket). . Zydus’ rabies vaccine manufacturing facility has received WHO pre-qualification, and is one of the largest rabies manufacturing facilities in India.</p>
    <div class="panel-group accordion" id="accordion3">
        <div class="panel panel-default">
            <div class="panel-heading">
                <h4 class="panel-title">
                    <a data-toggle="collapse" data-parent="#accordion3" href="#collapse03">Vaccine Pipeline
                        <i class="more-less glyphicon glyphicon-plus"></i></a>
                </h4>
            </div>
            <div id="collapse03" class="panel-collapse collapse">
                <div class="panel-body">
                    <!--<img src="https://www.zyduslife.com/public/images/vaccines-pipeline-q2-2020.jpg" class="img-responsive" alt="Vaccines Pipeline"/>
                    <img src="https://www.zyduslife.com/public/images/vaccines-pipeline-q2-2020-1.jpg" class="img-responsive" alt="Vaccines Pipeline"/>-->
                </div>
            </div>
        </div>

    </div>


<div class="imageTextSlider vaccineSlider">
        <div class="owl-carousel owl-theme owl-loaded">
            
        <div class="owl-stage-outer"><div class="owl-stage" style="transform: translate3d(0px, 0px, 0px); transition: all 0s ease 0s; width: 1140px;"><div class="owl-item active" style="width: 1140px;"><div class="item">
                <div class="col-md-8"><img src="https://www.zyduslife.com/public/images/ZyCoV-D-DNA.jpg" alt="VaxiFlu-4"></div>
                <div class="textBox">
                    <h4>ZyCoV-D®, world’s first Plasmid DNA vaccine approved for human use</h4>
                    <p>Approved in a two-dose regimen for 12 years and above, ZyCoV-D is a needle-free COVID vaccine.</p>
                </div>
				
            </div></div></div></div><div class="owl-nav disabled"><div class="owl-prev">prev</div><div class="owl-next">next</div></div><div class="owl-dots disabled"><div class="owl-dot active"><span></span></div></div></div>
    </div>
<p>Zydus acknowledges the support of  National Biopharma Mission, BIRAC, Department of Biotechnology, Government of India for funding the development, ICMR-National Institute of Virology, Pune for conduct of NHP Challenge study and PharmaJet Inc., Golden, CO, USA for providing  PharmaJet® Tropis® Needle-Free Injection System (NFIS) for vaccine delivery. We also thank all the researchers, clinical trial investigators, volunteers and regulatory agencies including the office of the Drug Controller General of India (DCGI) who supported us in the development of ZyCoV-D.</p>

    <div class="row borderbigBox custwidth" style="padding-bottom: 45px;">
        <div class="col-sm-6 col-md-6">
            <a href="https://www.zyduslife.com/public/pdf/ZyCov-D FactSheet.pdf" target="_blank" rel="noopener noreferrer"> Zycov-D Fact Sheet </a>
        </div>
        <div class="col-sm-6 col-md-6">
            <a href="https://www.zyduslife.com/public/pdf/PI ZYCOVD VACCINE 2ML VIAL.pdf" target="_blank" rel="noopener noreferrer"> PI Zycov-D vaccine 2ML vial </a>
        </div>
        <div class="col-sm-6 col-md-6">
            <a href="https://www.zyduslife.com/public/pdf/SmPc.pdf" target="_blank" rel="noopener noreferrer"> Zycov-D SmPc </a>
        </div>
    </div>





    <div class="imageTextSlider vaccineSlider">
        <div class="owl-carousel owl-theme owl-loaded">
            
        <div class="owl-stage-outer"><div class="owl-stage" style="transform: translate3d(0px, 0px, 0px); transition: all 0s ease 0s; width: 1140px;"><div class="owl-item active" style="width: 1140px;"><div class="item">
                <div class="col-md-8"><img src="https://www.zyduslife.com/public/images/innovation-3.jpg" alt="VaxiFlu-4"></div>
                <div class="textBox">
                    <h4>Vaxiflu-4 - India’s 1st Tetravalent Inactivated Influenza vaccine</h4>
                    <p>The vaccine provides protection from the four influenza viruses- H1N1, H3N2, Type B (Brisbane) and Type B (Phuket).</p>
                </div>
            </div></div></div></div><div class="owl-nav disabled"><div class="owl-prev">prev</div><div class="owl-next">next</div></div><div class="owl-dots disabled"><div class="owl-dot active"><span></span></div></div></div>
    </div>



    <h2>SCIENTIFIC ACTIVITIES <span id="scientificactivities" class="idName"></span></h2>
    <p><img src="https://www.zyduslife.com/public/images/scientific-activities.jpg" class="imgW100p" alt="Scientific Activities"></p>
    <p>A global knowledge sharing forum on innovation - The Ramanbhai Foundation  International Research Symposium</p>
    <p>The Ramanbhai Foundation International Symposium is a biannual series of symposia devoted to the discussion of new trends in the pharmaceutical industry with a view to promoting scientific excellence in drug discovery and development.</p>
    <div class="hideView-scientificActiv" style="display: none;">
        <p>Ramanbhai Foundation is named after a pathfinder, Late Mr. Ramanbhai B. Patel, who had dedicated his life to the quest of knowledge, as an academician, entrepreneur and a research scientist. He believed that new paths would surely open up if one has the creative will to discover it.</p>
        <p>For more than a decade, the Ramanbhai Foundation (RBF) international symposium has been bringing together experts from both the academia and industry across the world to share their insights on the latest developments in pharmaceutical research. Internationally acclaimed researchers converge to address the various aspects related to New Drug Discovery - with a focus on diabetes, cardiometabolic diseases, NASH, inflammation and infectious diseases. The keynote addresses over the past few years have been  delivered by the Nobel Laureates and Research Scientists of international acclaim. The symposium provides an insight into various aspects of drug discovery had an eminent panel of speakers and nearly 500 delegates from India and abroad participated in the symposium.</p>
        <p>To know more about the RBF Symposium and/or to participate, please visit <a href="http://www.rbfsymposium.net/" target="_blank" rel="noopener noreferrer">www.rbfsymposium.net</a></p>
    </div>

    <div class="text-center mb-65"><button class="btnCss scientificActivClick" type="button">Read More</button></div>
    <div class="row">
        <div class="col-md-7">
            <p><img src="https://www.zyduslife.com/public/images/collaborate.jpg" class="imgW100p" alt="Collaborate"></p>
        </div>
        <div class="col-md-5">
            <h2>COLLABORATE <span id="collaborate" class="idName"></span></h2>
            <p class="pb-0">Zydus is constantly exploring opportunities in pharma research under these specific categories:</p>
            <ul class="ulList">
                <li>Collaborative research and development</li>
                <li>In-licensing of technologies/NMEs</li>
                <li>Out-licensing/co-development of Zydus’ drug candidates</li>
            </ul>
            <p><strong>If you wish to partner with us, you may reach out to -</strong><br>
                Business Development <br>
                Zydus Research Centre<br>
                Sarkhej-Bavla N.H. No. 8A<br>
                Moraiya, Ahmedabad – 382210<br>
                Gujarat, India.</p>
            <p>Phone: +91-2717-665555<br>
                Fax: +91-2717-665353</p>
        </div>
    </div>
</div>
    <footer class="footer">
    <div class="container">
        <div class="col-md-9 col-xs-12">
            <div class="footer-section">
                <a href="company"><p class="title">The Company</p></a>
                <ul>
                    <li><a href="company#brand">The Brand</a></li>
                    <li><a href="company#mission">Mission</a></li>
                    <li><a href="company#community">Community</a></li>
					<li><a href="https://zyduslife.com/public/pdf/Zydus-Lifesciences-Limited-ESG-Report-2021-22.pdf" target="_blank">ESG Report 2021-22</a></li>
                    <li><a href="company#awards">Awards</a></li>
                    <li><a href="https://zyduslife.com/public/pdf/privacy-policy-draft-sm-rn.pdf" target="_blank">Privacy Policy</a></li>
                    <li><a href="https://zyduslife.com/public/pdf/Circular-for-MRP-Change.pdf" target="_blank">MRP Change</a></li>
                    <li><a href="https://zyduslife.com/public/pdf/Expanded-Access-Policy-Zydus-Discovery.pdf" target="_blank">Zydus Discovery DMCC</a></li>
                </ul>
            </div>
            <div class="footer-section">
                <a href="operations"><p class="title">Operations</p></a>
                <ul>
                    <li><a href="operations#indiabusiness">India Business</a></li>
                    <li><a href="operations#global">Global Presence</a></li>
                    <li><a href="https://zydusahl.com/">Animal Health</a></li>
                    <li><a href="operations#manufactur">Manufacturing</a></li>
                    <li><a href="operations#ehs">EHS Policy</a></li>
                </ul>
            </div>

            <div class="footer-section">
                <a href="research"><p class="title">Research</p></a>
                <ul>
                    <li><a href="research#researchpipeline">Focus</a></li>
                    <li><a href="research#newchemicalentities">New Chemical Entities</a></li>
                    <li><a href="research#biologics">Biologics</a></li>
                    <li><a href="research#vaccines">Vaccines</a></li>
                    <li><a href="research#researchpipeline">Research Pipeline</a></li>
                    <li><a href="research#scientificactivities">Scientific Activities</a></li>
                    <li><a href="research#collaborate">Collaborate</a></li>
                </ul>
            </div>
            <div class="footer-section mobile-width-50 mobile-clearfix">
                <a href="products"><p class="title">Products</p></a>
                <ul>
                    <li><a href="products#indiaformula">India Formulations</a></li>
                    <li><a href="products#generic">Generics</a></li>
                    <li><a href="products#zydusbiologics"> Zydus Biologics</a></li>
                    <li><a href="products#international"> International</a></li>
                </ul>
            </div>
            <div class="footer-section mobile-width-50">
                <a href="investorzone"><p class="title">Investor Zone</p></a>
                <ul>
                    <li><a href="investorzone#boardofdirector">Board Of Directors</a></li>
                    <li><a href="investorzone#compcommittee">Composition Of Committees</a></li>
                    <li><a href="investorzone#scheme">Scheme</a></li>
                    <li><a href="investorzone#financial">Financials</a></li>
                    <li><a href="investorzone#investorpresentation">Investor Presentation</a></li>
                    <li><a href="investorzone#teleconference">Teleconferences</a></li>
                    <li><a href="investorzone#agm">AGM</a></li>
                    <li><a href="investorzone#sharehs">Share Holder Service</a></li>
                    <li><a href="https://www.zyduslife.com/buyback2022">Buy Back 2022</a></li>					
                    <li><a href="investorzone#sharehp">Share Holding Pattern</a></li>
                    <li><a href="companypolicy">Policies</a></li>
                </ul>
            </div>
        </div>
        <div class="col-md-3 col-xs-12 right">
            <div class="footer-section mobile-clearfix">
                <a href="news"><p class="title">News Updates</p></a>
                <ul>
                    <li><a href="news#pressrelease">Press Releases</a></li>
                </ul>
            </div>
            <div class="footer-section">
                <a href="career"><p class="title">Careers</p></a>
				<div class="footer-static">
                <p class="green">Warning Regarding Fraudulent Job Postings:</p>
				<p class="green" onclick="div_show()" style="cursor:pointer">Authenticate your job offer letter</p>
                <a href="contactus" rel="noopener noreferrer"><p>India</p></a>
                <a href="contactus" rel="noopener noreferrer"><p>USA</p></a>
                
            </div>
			
			
                <a href="mediakit"><p class="title">Media Kit</p></a>
                <a href="contactus"><p class="title">Contact Us</p></a>
            </div>
            <div class="cf"></div>
            <div class="footer-static">
                
                <p class="green"><a href="https://www.zyduslife.com/adverse_event_reporting/" rel="noopener noreferrer">Adverse Event Reporting</a></p>
                <p class="green"><a href="contactus" rel="noopener noreferrer">Vendor Registration Portal</a></p>
                <p class="green"><a href="contactus" rel="noopener noreferrer">RFQ/AUCTION EVENT PARTICIPATION TRAINING GUIDE</a></p>
            </div>
        </div>
    </div>
	
	
	<div id="popup_wrapper">
  <div id="popupContact"> 
    <img src="https://www.zyduslife.com/public/images/close.png" id="close" onclick="div_hide()">
    <img src="https://www.zyduslife.com/public/images/hr-popup.png">
  </div>
</div>



    <style type="text/css">
	#popupContact img{
		max-width: 100%;
	}
#popup_wrapper {
    top: 0px;
    left: 0px;
    width: 100%;
    height: 100%;
    display: none;
    overflow: hidden !important;
    overflow: auto;
    position: fixed;
    background: #fff;
    -webkit-animation: fadein 2s;
    -moz-animation: fadein 2s;
    -ms-animation: fadein 2s;
    -o-animation: fadein 2s;
    animation: fadein 2s;
    font-family: Verdana, Geneva, sans-serif;
    z-index: 999;
}
@keyframes  fadein {
 from {
opacity: 0;
}
to {
	opacity: 1;
}
}
@-moz-keyframes fadein {
 from {
opacity: 0;
}
to {
	opacity: 1;
}
}
@-webkit-keyframes fadein {
 from {
opacity: 0;
}
to {
	opacity: 1;
}
}
@-ms-keyframes fadein {
 from {
opacity: 0;
}
to {
	opacity: 1;
}
}
@-o-keyframes fadein {
 from {
opacity: 0;
}
to {
	opacity: 1;
}
}
#popup_wrapper img#close {
    top: 15px;
    right: 15px;
    cursor: pointer;
    position: absolute;
}
#popup_wrapper div#popupContact {
    width: 100%;
    position: relative;
    margin: 0 auto;
    text-align: center;
}
    .modal-dialog.center {
        top: 50% !important;
        transform: translateY(-50%) !important;
        margin: 0 auto !important;
    }
    .center_text {
        text-align: center;
        color: #000;
    }
    div#qq{
        background: #000 !important;
        pointer-events: none !important;
    }
    .close{
        pointer-events: visible !important;
        opacity: .6 !important;
            float: initial !important;
    }
    .modal-content {
        pointer-events: visible !important;
    }
    </style>
    <p class="text-center copy-right"> Copyright © 2022 Zydus Group. All Rights Reserved.</p>
</footer>
<div class="modal fade" id="qq" role="dialog" style="display: none;">
    <div class="modal-dialog center">

        <!-- Modal content-->
        <div class="modal-content">
            <div class="modal-body">
                <!-- <button type="button" class="close" data-dismiss="modal">&times;</button> -->
                <p>
                    “By continuing to browse this site, you are consenting to the use of cookies for providing you optimum site performance, best user experience and tracking usage of our website to improve our product &amp; services offerings. We also utilize cookies on certain pages of our site to communicate with third party data suppliers in order to extrapolate your digital behavior. The information we receive is all aggregate and anonymous, but will include statistics such as demographics, online behavior, product interests and lifestyle. To find out more, please click  <a href="https://www.zyduslife.com/public/pdf/Cookie_Policy.pdf" rel="noopener noreferrer" target="_blank">here</a>.” 
                    
                    <!-- This site uses cookies to provide you with a personalized browsing experience. By using this site, you agree to our use of cookies as explained in our <a href="https://www.zyduslife.com/public/pdf/privacy-policy-draft-sm-rn.pdf" rel="noopener noreferrer" target="_blank">Privacy Policy</a>. Please read our <a href="https://www.zyduslife.com/public/pdf/privacy-policy-draft-sm-rn.pdf" rel="noopener noreferrer" target="_blank">Privacy Policy</a> for more information on how we use cookies and how you can manage them. -->
                </p>
                <div class="center_text">
                    <button type="button" class="close" data-dismiss="modal">Accept</button>
                </div>
            </div>

        </div>

    </div>
</div>
<!-- Modal -->
<div class="modal fade" id="myModal" role="dialog">
    <div class="modal-dialog">
        <!-- Modal content-->
        <div class="modal-content">
            <div class="modal-body">
                <button type="button" class="close" data-dismiss="modal">×</button>

                <div class="display-message subscribeLine" id="success" style="display:none;">
                    <span class="glyphicon glyphicon-envelope color-green" aria-hidden="true"></span>
                    <p>Thank you for subscription.</p>
                </div>

                <div class="display-message subscribeLine" id="failer" style="display:none;">
                    <span class="glyphicon glyphicon-envelope color-red" aria-hidden="true"></span>
                    <p>Your Email ID is already subscription</p>
                </div>


                <div id="main" style="display:block;">

                <div class="subscribeLine">
                    <span class="glyphicon glyphicon-envelope color-green" aria-hidden="true"></span>
                    <p>Subscribe to get the latest news and updates.</p>
                </div>
                <div class="subscribeBox">
                    <form name="scribe_form" id="scribe_form" novalidate="novalidate">
                        <input type="hidden" name="_token" value="urzFUnR2AMItMqJXzJaC9ZYTRXbC3yCu4E4m5AHW">
                        <input class="form-control required email" type="text" placeholder="Enter Your Email id" name="scribe" id="scribe" value="" aria-required="true">
                        <button type="submit" class="btn">Subscribe</button>
                    </form>
                </div>
                </div>
            </div>
        </div>
    </div>
</div><script type="text/javascript" src="https://www.zyduslife.com/public/js/jquery.min.js"></script>
<script type="text/javascript" src="https://www.zyduslife.com/public/js/bootstrap.min.js"></script>
<script type="text/javascript" src="https://www.zyduslife.com/public/js/general.js"></script>
<script type="text/javascript" src="https://www.zyduslife.com/public/js/owl.carousel.js"></script>
<script type="text/javascript" src="https://www.zyduslife.com/public/js/jquery.cookie.min.js">
</script>

<script>
    $(document).ready(function(){
        $("#myBtn").click(function(){
            $("#failer").hide();
            $("#success").hide();
            $("#main").show();
            $("#scribe").val('');
            $("#myModal").modal();
        });
    });
</script>

<script type="text/javascript" src="https://www.zyduslife.com/public/js/jquery.validate.js"></script>
<script type="text/javascript">
    $(document).ready(function () {
        $("#scribe_form").validate();


        $(document).ready(function() {
            if ($.cookie('pop') == null) {
                $('#qq').modal('show');
                $.cookie('pop', '1');
            }
        });
    });
</script>
<script type="text/javascript">
    $('#scribe_form').validate({
        submitHandler: function (form) {
            $.ajax({
                type: "POST",
                dataType: "json",
                url: 'https://www.zyduslife.com/scribesave',
                data: $(form).serialize(),
                success: function (data) {
                    if(data.code == 200) {
                        $("#failer").hide();
                        $("#success").show();
                        $("#main").hide();
                        $("#scribe").reset();
                    }else{
                        $("#failer").show();
                        $("#main").hide();
                        //$(".display-message").html('<h1>' + data.msg + '</h1>');
                        $("#scribe").reset();
                    }
                }
            });
        }
    });
</script>
<script>//function to display Popup

function div_show(){ 
	document.getElementById('popup_wrapper').style.display = "block";
}

//function to hide Popup
function div_hide(){ 
	document.getElementById('popup_wrapper').style.display = "none";
}
</script>

    <script>
    $(document).ready(function() {

        $('.imageTextSlider .owl-carousel').owlCarousel({
            items: 1,
            loop:false,
            pagination              : false,
            autoPlay                : false,
            afterMove               : 'slideChanged',
            startDragging           : 'pauseOnDragging',
            touchDrag               : false,
            mouseDrag               : false,
            autoHeight: false,
        });

        $(".hideView-research").hide();
        $(".researchClick").click(function(){
            $(".hideView-research").toggle();
            $(this).text("View More"==$(this).text()?"View Less":"View More");
        });

        $(".hideView-scientificAdvisory").hide();
        $(".scientificAdvisoryClick").click(function(){
            $(".hideView-scientificAdvisory").toggle();
            $(this).text("Read More"==$(this).text()?"Read Less":"Read More");
        });

        $(".hideView-scientificActiv").hide();
        $(".scientificActivClick").click(function(){
            $(".hideView-scientificActiv").toggle();
            $(this).text("Read More"==$(this).text()?"Read Less":"Read More");
        });
    });
</script>


</body></html>